Queen Mary spinout founders named among 50 Future Innovators.
Dr Madusha Peiris, founder of Elcella, and Dr Dave Ronan, founder of RoEx, are among 50 Future Innovators chosen by Universities UK to showcase founders creating the future.
/filters:format(webp)/prod01/channel_262/queen-mary-university-of-london/media/qmul/media/news/Web-future-innovators-brand-2.png)
Dr David Ronan and Dr Madusha Peiris
British university spinouts attract 17% of all UK venture capital investment, even as they account for just 5% of startups.
What makes university spinouts so investable?
Strong research foundations (92% of Queen Mary’s is world leading or internationally excellent), defensible intellectual property (Queen Mary consistently achieves top KEF rating for IP and Commercialisation), and unique expertise.
But Britain risks losing ground, especially at the scaleup stage. The United States, which already has over triple the startup funding, invests nine times as much in scaleups as Britain does.
Through Future Innovators, Universities UK are working with founders, universities, and leaders from business, investment, and government to establish what it will take to become the best place in the world to start and grow an innovative business.
The initiative begins with 50 Future Innovators, a celebration of individuals whose innovative work has been meaningfully catalysed by a connection to a university and is creating real impact, including two spinout founders from Queen Mary University of London.
The judges, drawn from across business, research, the arts and public life, selected the final fifty based on being groundbreaking, contemporary, university-linked, and impactful.
The judges were Dr Darren Henley CBE, Chief Executive of Arts Council England; Dr Anne-Marie Imafidon MBE, CEO of Stemettes; Baroness Beeban Kidron OBE, Honorary President, founder and former Chair of the 5Rights Foundation; Baroness Martha Lane Fox MBE, Co-founder of lastminute.com; Professor Dame Ottoline Leyser DBE FRS, Regius Professor of Botany at the University of Cambridge, Former Chief Executive of UKRI.
Dr Madusha Peiris: Founder of Elcella, the world’s first product proven to release the body’s own appetite regulating hormones.
Elcella is a natural alternative to weight-loss drugs, grounded in a decade of Queen Mary research. Conventional weight-loss drugs use synthetic GLP-1 to suppress appetite. Elcella uses nutrients to stimulate release of the body’s own GLP-1 and PYY to regulate appetite naturally without side effects.
Dr Madusha Peiris discovered the entire gut can detect different types of nutrients, and that specific combinations of nutrients unlock L-cells in the colon, prompting release of GLP-1 and PYY. The underpinning research was published in high-impact journals including Gut. Queen Mary supported three clinical trials, run by co-founder Dr Rubina Aktar.
Elcella launched in the UK in 2025 and is now expanding into Europe and North America. Queen Mary Innovation supported the path to Elcella’s commercial success, including patenting, market validation, business planning, securing investment, and initial publicity. Dr Peiris took a year of entrepreneurial sabbatical to focus on building her business, using the Queen Mary Enterprise Zone as her initial base.
The health risks of being overweight are well-documented. Elcella is helping people who have struggled with their weight for a long time, have repeatedly tried to get healthy, and who seek a drug-free, natural and scientifically grounded approach to weight loss.
Weight-loss drugs are becoming ever more popular, but they don’t support gut health. Instead, they create a drug dependency that leads to weight regain as the appetite resurges in the absence of artificial hormones. With Elcella, the gut gets healthier over time and learns to regulate itself better.
Invented, commercialised, and manufactured in the UK, Elcella demonstrates how university research can become a high-growth venture addressing one of the world's most urgent health challenges. By combining world-leading gut-health science with entrepreneurship, Dr Peiris has transformed fundamental research into an innovation with international reach and the potential to improve health outcomes for millions of people while creating economic value for the UK.
Dr Dave Ronan: Founder of RoEx, studio-quality sound with intelligent audio tools.
RoEx supports artists by removing the need for expensive studio equipment or complex plugins for mixing and mastering, so artists can focus purely on creativity.
Most independent tracks on Spotify and Apple Music fail basic mixing and mastering standards. UnitedMasters reported that properly mastered tracks see 34% more streams in their first three months, leaving unmastered tracks losing listeners before they're even heard. RoEx gives any artist studio-quality sound in minutes.
Dr David Ronan spent his PhD at Queen Mary University of London's Centre for Digital Music working with co-founder Prof Josh Reiss to solve a problem no one had cracked: teaching software to make the same judgment calls a professional mixing engineer makes, balancing, shaping and polishing a song, rather than just applying a preset. That research became RoEx.
Since launching in 2022, RoEx has processed over 7 million tracks, supporting millions of artists worldwide, and continues to do collaborative research with Queen Mary.
Queen Mary Innovation guided the path to commercialisation, including patenting, market validation and business planning, providing office space in Queen Mary's Enterprise Zone, and investing in RoEx alongside Haatch Ventures.
RoEx stands out as an example of AI working with artists, not against them. Looking ahead, RoEx is extending this model into live production tools and post-production workflows for film and TV, bringing the same accessible, artist-first approach to new creative industries.
At Queen Mary, every student, researcher, staff member, and recent alumni can access entrepreneurship support. Visit QUEST to get started.
Subscribe to Queen Mary Connect to stay up to date with the best of Queen Mary Research and Innovation.